Atria Wealth Solutions Inc. Increases Stake in DaVita Inc. (NYSE:DVA)

Atria Wealth Solutions Inc. grew its holdings in shares of DaVita Inc. (NYSE:DVA) by 37.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,745 shares of the company’s stock after purchasing an additional 1,301 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in DaVita were worth $497,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of DVA. Vanguard Group Inc. raised its holdings in DaVita by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 6,175,029 shares of the company’s stock valued at $583,725,000 after acquiring an additional 65,526 shares during the period. Invesco Ltd. increased its holdings in shares of DaVita by 21.3% in the 3rd quarter. Invesco Ltd. now owns 1,667,255 shares of the company’s stock worth $157,606,000 after buying an additional 292,767 shares during the last quarter. Deutsche Bank AG raised its position in shares of DaVita by 421.8% during the 3rd quarter. Deutsche Bank AG now owns 1,095,081 shares of the company’s stock valued at $103,518,000 after buying an additional 885,195 shares in the last quarter. Lazard Asset Management LLC lifted its holdings in shares of DaVita by 8.7% during the 3rd quarter. Lazard Asset Management LLC now owns 845,416 shares of the company’s stock worth $79,916,000 after acquiring an additional 67,970 shares during the last quarter. Finally, Northern Trust Corp grew its position in DaVita by 15.7% in the third quarter. Northern Trust Corp now owns 834,608 shares of the company’s stock worth $78,895,000 after acquiring an additional 113,508 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on DVA. Truist Financial increased their price objective on DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a research report on Tuesday, February 20th. StockNews.com raised shares of DaVita from a “buy” rating to a “strong-buy” rating in a report on Thursday, April 25th. UBS Group boosted their price target on shares of DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a research note on Wednesday, February 14th. TheStreet raised DaVita from a “c+” rating to a “b-” rating in a research note on Wednesday, February 7th. Finally, Barclays began coverage on DaVita in a research note on Wednesday, March 6th. They issued an “equal weight” rating and a $133.00 target price for the company. Two research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.50.

Insider Activity

In related news, CEO Javier Rodriguez sold 67,603 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the completion of the sale, the chief executive officer now owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Javier Rodriguez sold 67,603 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the transaction, the chief executive officer now owns 488,697 shares in the company, valued at $61,629,578.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider James O. Hearty sold 26,164 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the completion of the sale, the insider now owns 20,264 shares of the company’s stock, valued at $2,424,384.96. The disclosure for this sale can be found here. Over the last three months, insiders have sold 134,540 shares of company stock valued at $16,551,071. Company insiders own 1.40% of the company’s stock.

DaVita Price Performance

DVA stock opened at $134.45 on Monday. The stock has a market capitalization of $11.79 billion, a price-to-earnings ratio of 15.28, a PEG ratio of 1.17 and a beta of 1.04. The firm’s 50-day moving average price is $133.71 and its two-hundred day moving average price is $112.84. The company has a current ratio of 1.43, a quick ratio of 1.37 and a debt-to-equity ratio of 7.95. DaVita Inc. has a 12-month low of $71.51 and a 12-month high of $145.04.

DaVita (NYSE:DVA) last posted its earnings results on Thursday, May 2nd. The company reported $2.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.95 by $0.43. The company had revenue of $3.07 billion for the quarter, compared to analysts’ expectations of $3.03 billion. DaVita had a return on equity of 68.52% and a net margin of 6.61%. DaVita’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period last year, the firm earned $1.58 earnings per share. As a group, equities analysts predict that DaVita Inc. will post 9.49 earnings per share for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.